← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	918	+7	+0.8%	$44.2B
2	2 Danaher DHR $158B	889	-23	-3%	$41.7B
3	3 Novartis NVS $279B	875	+27	+3%	$22.2B
4	4 Agilent Technologies A $49.1B	579	-12	-2%	$15.9B
5	5 Illumina ILMN $41B	480	+22	+5%	$22.6B
6	6 Regeneron Pharmaceuticals REGN $80.1B	474	+26	+6%	$25.9B
7	7 Revvity RVTY $17B	324	0	0%	$4.58B
8	8 Myriad Genetics MYGN $397M	276	-8	-3%	$3.74B
9	9 Charles River Laboratories CRL $14.4B	255	-7	-3%	$2.79B
10	10 Ionis Pharmaceuticals IONS $7.1B	240	+2	+0.8%	$4.11B
11	11 Bruker BRKR $8.47B	203	+13	+7%	$2.09B
12	12 Alnylam Pharmaceuticals ALNY $30B	186	-8	-4%	$4.61B
13	13 DELISTED SANGAMO THERAPEUTICS INC SGMO	157	+1	+0.6%	$527M
14	14 Azenta AZTA $1.63B	143	-7	-5%	$662M
15	15 DELISTED bluebird bio BLUE	123	+19	+18%	$846M
16	16 Sarepta Therapeutics SRPT $1.78B	123	-5	-4%	$548M
17	17 Arrowhead Research ARWR $8.25B	110	-2	-2%	$542M
18	18 Precigen PGEN $2.64B	102	-5	-5%	$1.64B
19	19 Ultragenyx Pharmaceutical RARE $1.47B	100	+19	+23%	$1.5B
20	20 Standard BioTools LAB $248M	99	-5	-5%	$702M
21	21 PTC Therapeutics PTCT $4.98B	99	+15	+18%	$1.07B
22	ISEE 22 DELISTED IVERIC bio, Inc. Common Stock ISEE	92	-6	-6%	$1.13B
23	23 Pacific Biosciences PACB $619M	88	+2	+2%	$178M
24	24 DELISTED CATALENT, INC. CTLT	80	+80	–	$3.14B
25	25 Invesco Biotechnology & Genome ETF PBE $421M	70	-4	-5%	$116M